John Fung to Antigens, Differentiation
This is a "connection" page, showing publications John Fung has written about Antigens, Differentiation.
Connection Strength
0.409
-
Prolonged survival of heart allografts transduced with AAV-CTLA4Ig. Microsurgery. 2003; 23(5):489-93.
Score: 0.052
-
Marked prolongation of cardiac allograft survival by dendritic cells genetically engineered with NF-kappa B oligodeoxyribonucleotide decoys and adenoviral vectors encoding CTLA4-Ig. J Immunol. 2002 Sep 15; 169(6):3382-91.
Score: 0.051
-
Transfection with genes encoding CTLA4Ig mediated by adenoassociated virus vectors prolongs survival of heart allografts. Transplant Proc. 2001 Feb-Mar; 33(1-2):604.
Score: 0.045
-
Administration of CTLA4-Ig enhances the incidence of hamster-to-rat xenogeneic bone marrow engraftment and alters the presentation of graft-vs-host disease. Transplant Proc. 2000 Aug; 32(5):1032-3.
Score: 0.044
-
Treatment with CTLA4-Ig inhibits rejection of liver allografts from FIt3-ligand-treated donors. Transplant Proc. 1999 Feb-Mar; 31(1-2):453.
Score: 0.039
-
Transduction of dendritic cells with adenoviral vectors encoding CTLA4-Ig markedly reduces their allostimulatory activity. Transplant Proc. 1999 Feb-Mar; 31(1-2):797.
Score: 0.039
-
Prevention of T-cell activation by rhCTLA4-Ig and anti-CD40L monoclonal antibody results in indefinite islet allograft survival. Transplant Proc. 1999 Feb-Mar; 31(1-2):1242-3.
Score: 0.039
-
Systemic administration of CTLA4-Ig or anti-CD40 ligand antibody inhibits second-set rejection of mouse liver allografts. Transplant Proc. 1999 Feb-Mar; 31(1-2):1244.
Score: 0.039
-
Prevention of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and anti-CD40 ligand monoclonal antibody. Transplantation. 1997 Dec 27; 64(12):1838-43.
Score: 0.036
-
Costimulation blockade promotes the apoptotic death of graft-infiltrating T cells and prolongs survival of hepatic allografts from FLT3L-treated donors. Transplantation. 2001 Oct 27; 72(8):1423-32.
Score: 0.012
-
Monitoring the patient off immunosuppression. Conceptual framework for a proposed tolerance assay study in liver transplant recipients. Transplantation. 2001 Oct 27; 72(8 Suppl):S13-22.
Score: 0.012